Corporación COFAR

What Corporación COFAR does

Corporación COFAR is a privately held, for-profit pharmaceutical manufacturer headquartered in La Paz, Bolivia. The company identifies itself as specializing in pharmaceutical manufacturing with triple certification, positioning the business around regulated, quality-controlled production of healthcare products for the Bolivian market. With a headcount of 501-1000 employees, COFAR operates at a scale that is notable within Bolivia's domestic pharmaceutical sector, which historically has been relatively fragmented.

The company's stated differentiator centers on its triple certification framework, which in pharmaceutical manufacturing typically encompasses GMP (Good Manufacturing Practice), quality management systems, and regulatory/health authority compliance — assets that create substantial barriers to entry in regulated drug production. Beyond this claim, the underlying product portfolio, specific therapeutic categories served, and customer base are not documented in the available source material.

The business model is not detailed in the input data; there are no disclosed pricing structures, no identified distribution channels, no named customers, no partnership agreements, and no revenue figures. The company website (cofar.com.bo) was inaccessible during data collection, returning only a loading/verification page. As a result, go-to-market mechanics, customer segmentation, geographic footprint beyond Bolivia, and ownership structure cannot be characterized from the available evidence.

Name

Corporación COFAR

Website

https://cofar.com.bo

Company type

Private

Operating status

Operating

Headcount range

501–1,000 employees

Short description

Corporación COFAR is a privately held pharmaceutical manufacturer headquartered in La Paz, Bolivia, operating with 501-1000 employees and emphasizing triple certification in its quality-controlled drug production for the domestic healthcare market.

Ownership category

akta.pro rank

Product category

Pharmaceutical Manufacturing

NAICS

Pharmaceutical Preparation Manufacturing (325412)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Compounding Ingredient & API Distributors (Pharma Supply) (HLAIAJAO)

akta.pro secondary industry

Government & Public-Sector Pharmaceutical Supply (Tender/Prime Vendor) (HLAIAJAF)

Keywords

• Pharmaceutical manufacturing
• Healthcare products
• Triple certified drugs
• Generic medicines
• Bolivian pharma

Headquarters

HQ city

La Paz

HQ country

Bolivia

HQ region

Latin America

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Operations, Personnel, Technology or R&D, Marketing or Sales

Core offering

Corporación COFAR is a Bolivian pharmaceutical manufacturer that produces and supplies quality-assured healthcare products under a triple-certification regime. The company serves the domestic healthcare market from its La Paz base, manufacturing drug products for downstream healthcare distribution channels.

Differentiator

Problem solved

Functional benefit

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Direct peers

• EMS Pharma: Brazil's largest generics manufacturer by volume, exporting across Latin America. Comparable to COFAR as a high-volume generics producer whose regional expansion represents both a competitive threat and a benchmark for scale in the category.
• Genomma Lab Internacional: Mexican pharmaceutical company with a strong OTC and personal-care portfolio across Latin America, including Andean markets. Comparable to COFAR as a Latin American manufacturer leveraging regional distribution and brand-led positioning.
• Laboratorios Bagó: Major Argentine pharmaceutical manufacturer with a long-standing commercial presence in Bolivia, producing branded and generic medicines across most major therapeutic categories — directly comparable to COFAR as a Latin American pharma manufacturer serving the Andean market.
• Grupo Roemmers: One of the largest Argentine pharmaceutical groups, manufacturing branded and generic pharmaceuticals with regional Latin American distribution. Highly comparable as a mid-to-large Latin American pharma manufacturer competing in the same regional supply landscape as COFAR.
• Eurofarma Laboratórios: Brazilian pharmaceutical manufacturer with one of the broadest generic and branded portfolios in Latin America, actively expanding into Andean markets. Comparable to COFAR as a scaled regional generics manufacturer competing for the same institutional and retail demand.
• Laboratorios Richmond: Argentine pharmaceutical manufacturer with a portfolio spanning branded generics, specialty, and biotech products, and active export presence across Latin America. Comparable to COFAR as a regionally focused manufacturer with quality-certified operations.
• Aché Laboratórios: Brazilian pharmaceutical manufacturer with a mix of branded generics, prescription, and OTC products and growing Latin American footprint. Comparable to COFAR as a mid-to-large regional manufacturer targeting similar therapeutic and institutional channels.

Broad incumbents

• Novartis: Global pharmaceutical manufacturer with commercial operations throughout Latin America. Comparable to COFAR as a broader incumbent whose branded portfolio and institutional contracts compete directly with locally manufactured alternatives in the Bolivian market.
• Bayer: Global life sciences company with pharmaceutical manufacturing and a significant presence in Bolivia and across Latin America. Comparable to COFAR as a broader incumbent competing in overlapping therapeutic categories and institutional tenders, though with vastly greater scale and portfolio breadth.
• Sanofi: Global pharmaceutical manufacturer with established commercial and sometimes manufacturing presence in Latin America. Comparable to COFAR as a broader incumbent whose vaccines, specialty, and generics portfolios overlap with locally manufactured categories in Bolivia.

Market position

Strengths3 records

Weaknesses3 records

Competitive moat2 records

Key risks5 records

Key highlights4 records

Customer concentration

• Facebookfacebook.com/LaboratoriosCofar
• LinkedInlinkedin.com/company/corporacion-cofar

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Corporación COFAR